NASHUA, N.H., July 25 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that the Company’s second quarter financial results will be announced before market open on Thursday, August 9. iCAD management will discuss the results during a conference call scheduled for at 10:00 am ET.
Shareholders and other interested parties may participate in the conference call by dialing +1 866-761-0748 (domestic) or +1 617-614-2706 (international) and entering passcode 56865575 a few minutes before 10:00 am ET on August 9, 2007. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.icadmed.com.
A replay of the conference call will be accessible 2 hours after its completion through August 16, 2007 by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering passcode 17941240. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com and http://www.icadmed.com.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, Executive VP and CFO at 603-882-5200 or via email at ddeptula@icadmed.com
For iCAD Investor Relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD, Inc.
CONTACT: Darlene Deptula-Hicks, Executive VP and CFO of iCAD, Inc.,+1-603-882-5200, ddeptula@icadmed.com; or Investor Relations, Kevin McGrathof Cameron Associates, +1-212-245-4577, kevin@cameronassoc.com; or PublicRelations, Wendy Ryan of Schwartz Communications, +1-781-684-0770,icad@schwartz-pr.com, both for iCAD, Inc.
